BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") will present data for selected assets from its diversified oncology ...

These initiation patterns are shifting as research uncovers ... Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme. Please see the poster for all other authors’ relevant financial disclosures.

Disclosures: Riedl reports receiving research ... Sanofi-Regeneron and Takeda; and having speaker roles with CSL Behring, Grifols, Pharming and Takeda. Please see the poster for all other authors ...

Von Abo interned at Regeneron in 2024 and developed a novel high-throughput ... as conducting the lab classes themselves,” she said. “While explaining my research at poster presentations, I also ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...

The Tarrytown, New York-based company said it had profit of $7.27 per share. Earnings, adjusted for one-time gains and costs, came to $8.22 per share. The results fell short of Wall Street ...

Regeneron Pharmaceuticals stock was among the ... We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in ...

Regeneron (REGN) came out with quarterly earnings ... (s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements ...

For 2025, Regeneron reiterated its projection for research-and-development spending in a range between $5.56 billion and $5.795 billion. The company cut the top end of its forecasted range for 2025 ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron ... jobs and expanding research, preclinical ...

Before you invest in Regeneron Pharmaceuticals, Inc. (REGN), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks ...